DXCM vs MANE
Dexcom vs Veradermics, Incorporated — AI-powered side-by-side comparison
VS
MANE
Veradermics, Incorporated
69
Buy
| Metric | DXCM | MANE |
|---|
| AI Score |
63
|
69
|
| Price |
$89.16
|
$102.33
|
| P/E Ratio |
35.16×
|
-46.01×
|
| ROE |
30.5%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.5%
|
0.0%
|
| Debt / Equity |
0.53×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.4
|
29.2
|
| Beta |
1.41
|
1.3492
|
| Expected Upside |
+2.3%
|
+18.2%
|
AI Committee View
Current Innellis committee reasoning for DXCM versus MANE.
MANE leads by 6 points.
MANE scores 69/100 (Buy) versus DXCM at 63/100 (Buy).
DXCM Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- RSI at 75 is in overbought territory — Technical
MANE Committee View
100% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is sector concentration is already high (hhi 3063.01). The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- MACD histogram negative -- bearish momentum — Technical